Profile Response Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com


Molecular Profile CD274 positive
Therapy Cisplatin + Paclitaxel + Toripalimab-tpzi
Indication/Tumor Type esophagus squamous cell carcinoma
Response Type predicted - sensitive

Filtering

  • Case insensitive filtering will display rows if any text in any cell matches the filter term
  • Use simple literal full or partial string matches
  • Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
  • Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

  • Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Molecular Profile Indication/Tumor Type Response Type Therapy Name Approval Status Evidence Type Efficacy Evidence References
CD274 positive esophagus squamous cell carcinoma predicted - sensitive Cisplatin + Paclitaxel + Toripalimab-tpzi Phase III Actionable In a post hoc analysis of a Phase III trial (JUPITER-06), addition of Loqtorz (toripalimab-tpzi) to paclitaxel and cisplatin improved progression-free survival (5.7 vs 5.5 mo, HR 0.59, p=0.0005 TPS H; 6.1 vs 5.7 mo, HR 0.59, p=0.0089 TPS L) and median overall survival (16.9 vs 10.8 mo, HR=0.61, p=0.0133 TPS H; not reached vs 11.6 mo, HR=0.63, p=0.0913 TPS L) in patients with esophagus squamous cell carcinoma with low (L, TPS<1%) or high (H, TPS>=1%) CD274 (PD-L1) expression (PMID: 36473145). 36473145
PubMed Id Reference Title Details
(36473145) Clinical Benefit of First-Line Programmed Death-1 Antibody Plus Chemotherapy in Low Programmed Cell Death Ligand 1-Expressing Esophageal Squamous Cell Carcinoma: A Post Hoc Analysis of JUPITER-06 and Meta-Analysis. Full reference...